Literature DB >> 35221851

Magnetic Resonance Imaging in Cardiac Amyloidosis: Unraveling the Stealth Entity.

Omair Shah1, Naseer Choh1, Tahleel Shera1, Faiz Shera1, Tariq Gojwari1, Feroze Shaheen1, Irfan Robbani1.   

Abstract

Amyloidosis is a systemic disease involving many organs. Cardiac involvement is a significant cause of morbidity and mortality in these patients. Diagnosis of cardiac amyloidosis is based on endomyocardial biopsy which however is invasive and associated with complications. Noninvasive methods of diagnosis include magnetic resonance imaging (MRI) with various methods and sequences involved. Our study aims at describing MRI features of cardiac amyloidosis including new imaging sequences and to prognosticate the patients based on imaging features. We included 35 patients with suspected cardiac amyloidosis who underwent MRI at our center over 4 years. All images were retrieved from our archive and assessed by an experienced radiologist. Common morphological features in our patients included increased wall thickness of left ventricle (LV) (16. 1 ± 4.1 mm), right ventricle (RV) (6.3 ± 1.1 mm), and interatrial septum (6.2 ± 0.8 mm). Global late gadolinium enhancement (LGE) ( n  = 21 [65%]) including subendocardial or transmural was the most common pattern followed by patchy enhancement. Global transmural LGE was associated with worse prognosis. Four types of myocardial nulling patterns were observed on postcontrast time to invert (TI) scout imaging: normal nulling pattern (myocardium nulls after blood and coincident with spleen) and abnormal nulling pattern (ANP) which is further divided into three types: Type 1-myocardium nulls before blood pool but coincident with spleen, Type 2-myocardium nulling coincident with blood but not coincident with spleen, and Type 3-features of both Type 1 and Type 2. Type 3 ANP was the most common ( n  = 23) nulling pattern in our patients. Cardiac MRI is an essential in noninvasive diagnosis of cardiac amyloidosis. Transmural global LGE serves as a poor prognosticator in these patients. "Three-tier" TI scout imaging is essential to avoid false-negative enhancement results. Type 3 ANP is the most specific nulling pattern in cardiac amyloidosis. International College of Angiology. This article is published by Thieme.

Entities:  

Keywords:  abnormal nulling pattern; balanced single shot free precession; echocardiography; magnetic resonance imaging; time to invert

Year:  2021        PMID: 35221851      PMCID: PMC8881106          DOI: 10.1055/s-0041-1735948

Source DB:  PubMed          Journal:  Int J Angiol        ISSN: 1061-1711


  20 in total

1.  Clinical profile and outcome of idiopathic restrictive cardiomyopathy.

Authors:  N M Ammash; J B Seward; K R Bailey; W D Edwards; A J Tajik
Journal:  Circulation       Date:  2000-05-30       Impact factor: 29.690

2.  Diagnostic value of abdominal wall fat pad biopsy in senile systemic amyloidosis.

Authors:  Shu-ichi Ikeda; Yoshiki Sekijima; Kana Tojo; Jun Koyama
Journal:  Amyloid       Date:  2011-10-17       Impact factor: 7.141

3.  Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis.

Authors:  Dermot Phelan; Patrick Collier; Paaladinesh Thavendiranathan; Zoran B Popović; Mazen Hanna; Juan Carlos Plana; Thomas H Marwick; James D Thomas
Journal:  Heart       Date:  2012-08-03       Impact factor: 5.994

4.  Cardiovascular magnetic resonance in cardiac amyloidosis.

Authors:  Alicia Maria Maceira; Jayshree Joshi; Sanjay Kumar Prasad; James Charles Moon; Enrica Perugini; Idris Harding; Mary Noelle Sheppard; Philip Alexander Poole-Wilson; Philip Nigel Hawkins; Dudley John Pennell
Journal:  Circulation       Date:  2005-01-03       Impact factor: 29.690

5.  Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis.

Authors:  Imran S Syed; James F Glockner; Dali Feng; Philip A Araoz; Matthew W Martinez; William D Edwards; Morie A Gertz; Angela Dispenzieri; Jae K Oh; Diego Bellavia; A Jamil Tajik; Martha Grogan
Journal:  JACC Cardiovasc Imaging       Date:  2010-02

6.  MR findings in cardiac amyloidosis.

Authors:  Rohan I vanden Driesen; Richard E Slaughter; Wendy E Strugnell
Journal:  AJR Am J Roentgenol       Date:  2006-06       Impact factor: 3.959

Review 7.  Magnetic resonance imaging of primary cardiomyopathies.

Authors:  Rafaela Soler; Esther Rodríguez; Carmen Remuiñán; María José Bello; Alejandro Díaz
Journal:  J Comput Assist Tomogr       Date:  2003 Sep-Oct       Impact factor: 1.826

8.  Imaging of cardiac amyloidosis by (99m)Tc-PYP scintigraphy.

Authors:  Vasileios Papantoniou; Pipitsa Valsamaki; Stathis Kastritis; Spyridon Tsiouris; Zisis Delichas; Yiannis Papantoniou; Maria Tsiouma; Theodoros Athanasoulis; Andreas Fotopoulos; Meletios Athanasios Dimopoulos
Journal:  Hell J Nucl Med       Date:  2015 Sep-Dec       Impact factor: 1.102

9.  Echocardiographic findings in systemic amyloidosis: spectrum of cardiac involvement and relation to survival.

Authors:  L Cueto-Garcia; G S Reeder; R A Kyle; D L Wood; J B Seward; J Naessens; K P Offord; P R Greipp; W D Edwards; A J Tajik
Journal:  J Am Coll Cardiol       Date:  1985-10       Impact factor: 24.094

10.  Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis.

Authors:  Marianna Fontana; Silvia Pica; Patricia Reant; Amna Abdel-Gadir; Thomas A Treibel; Sanjay M Banypersad; Viviana Maestrini; William Barcella; Stefania Rosmini; Heerajnarain Bulluck; Rabya H Sayed; Ketna Patel; Shameem Mamhood; Chiara Bucciarelli-Ducci; Carol J Whelan; Anna S Herrey; Helen J Lachmann; Ashutosh D Wechalekar; Charlotte H Manisty; Eric B Schelbert; Peter Kellman; Julian D Gillmore; Philip N Hawkins; James C Moon
Journal:  Circulation       Date:  2015-09-11       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.